Benzinga's Top #PreMarket Gainers

shares rose 16.44 percent to $6.09 in pre-market trading after the company reported positive End-of-Phase 2 meeting with the FDA and Phase 3 development strategy for trabodenoson, a novel treatment for glaucoma.

shares rose 13.40 percent to $61.44 in pre-market trading after the company reported stronger-than-expected results for the second quarter.

shares climbed 11.11 percent to $47.00 in pre-market trading after the company reported upbeat Q2 results.

gained 10.55 percent to $33.95 in pre-market trading after the company reported stronger-than-expected results for the second quarter.

shares climbed 9.33 percent to $5.51 in pre-market trading on better-than-expected Q2 results.